These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9220319)

  • 1. A prospective randomized evaluation of the prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2.
    Cormier JN; Hurst R; Vasselli J; Lee D; Kim CJ; McKee M; Venzon D; White D; Marincola FM; Rosenberg SA
    J Immunother; 1997 Jul; 20(4):292-300. PubMed ID: 9220319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.
    Guleria AS; Yang JC; Topalian SL; Weber JS; Parkinson DR; MacFarlane MP; White RL; Steinberg SM; White DE; Einhorn JH
    J Clin Oncol; 1994 Dec; 12(12):2714-22. PubMed ID: 7989949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
    Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S
    Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer.
    Marroquin CE; White DE; Steinberg SM; Rosenberg SA; Schwartzentruber DJ
    J Immunother; 2000; 23(3):387-92. PubMed ID: 10838668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
    Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
    JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.
    Yang JC; Topalian SL; Parkinson D; Schwartzentruber DJ; Weber JS; Ettinghausen SE; White DE; Steinberg SM; Cole DJ; Kim HI
    J Clin Oncol; 1994 Aug; 12(8):1572-6. PubMed ID: 8040669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose dopamine induces early recovery of recombinant interleukin-2--impaired renal function.
    Palmieri G; Morabito A; Lauria R; Montesarchio V; Matano E; Memoli B; Libetta C; Rea A; Merola C; Correale P
    Eur J Cancer; 1993; 29A(8):1119-22. PubMed ID: 8518023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2.
    Spanknebel K; Cheung KY; Stoutenburg J; Hurst-Wicker K; Hesdorffer C; Deraffele G; Kaufman HL
    Ann Surg Oncol; 2005 May; 12(5):381-90. PubMed ID: 15915372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma.
    MacFarlane MP; Yang JC; Guleria AS; White RL; Seipp CA; Einhorn JH; White DE; Rosenberg SA
    Cancer; 1995 Feb; 75(4):1030-7. PubMed ID: 7842405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2.
    Yang JC; Topalian SL; Schwartzentruber DJ; Parkinson DR; Marincola FM; Weber JS; Seipp CA; White DE; Rosenberg SA
    Cancer; 1995 Aug; 76(4):687-94. PubMed ID: 8625167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose intravenous bolus interleukin-2 with interferon-alpha therapy for metastatic melanoma and renal cell carcinoma.
    Karp SE
    J Immunother; 1998 Jan; 21(1):56-61. PubMed ID: 9456437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of total parental nutrition (TPN) during high-dose interleukin-2 treatment for metastatic cancer.
    Samlowski WE; Wiebke G; McMurry M; Mori M; Ward JH
    J Immunother; 1998 Jan; 21(1):65-74. PubMed ID: 9456439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.
    Thompson JA; Bianco JA; Benyunes MC; Neubauer MA; Slattery JT; Fefer A
    Cancer Res; 1994 Jul; 54(13):3436-41. PubMed ID: 8012963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2.
    Lindsey KR; Rosenberg SA; Sherry RM
    J Clin Oncol; 2000 May; 18(9):1954-9. PubMed ID: 10784637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.
    Margolin K; Aronson FR; Sznol M; Atkins MB; Gucalp R; Fisher RI; Sunderland M; Doroshow JH; Ernest ML; Mier JW
    J Immunother Emphasis Tumor Immunol; 1994 Feb; 15(2):147-53. PubMed ID: 8136948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
    Yang JC; Rosenberg SA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S79-84. PubMed ID: 9457400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hyperdynamic hemodynamics following high-dose interleukin 2-interferon alpha therapy in patients with metastatic renal cell carcinoma. Immunotherapy as a clinical sepsis model?].
    Finck-Seelen ; Lampert R; Brandt L
    Anaesthesist; 1996 Dec; 45(12):1171-8. PubMed ID: 9065251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b.
    Sznol M; Mier JW; Sparano J; Gaynor ER; Weiss GR; Margolin KA; Bar MH; Hawkins MJ; Atkins MB; Dutcher JP
    J Biol Response Mod; 1990 Dec; 9(6):529-37. PubMed ID: 2074439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.